Lyora Therapeutics Raises $2.5 Million in Pre-Seed Funding
Lyora Therapeutics, a biotech company based in Providence, Rhode Island, has successfully raised $2.5 million in a pre-seed funding round as of July 15, 2026. The company focuses on developing genetic medicines aimed at restoring and preserving sight.
Company Overview
Founded and led by CEO Pam Stetkiewicz, Lyora Therapeutics is dedicated to creating innovative genetic therapies that address vision-related health issues. The company's mission is to leverage cutting-edge genetic technologies to offer solutions for individuals suffering from sight impairment.
Funding Details
The recent funding round did not specify any lead or additional investors. It marks a significant step for Lyora Therapeutics as it seeks to advance its research and development efforts in the field of genetic medicine.
Planned Use of Funds
While specific plans for the use of the $2.5 million were not detailed, it is expected that the funds will be allocated towards furthering research and development activities. This may include expanding the company's capabilities in genetic medicine and potentially scaling up operations to bring their therapies closer to the market.
Location and Leadership
Operating out of Providence, Rhode Island, Lyora Therapeutics benefits from the leadership of CEO Pam Stetkiewicz. Her vision for the company is to make significant strides in genetic medicine that can profoundly impact the lives of those with vision impairments.
For more information about Lyora Therapeutics and their mission, visit their website at lyoratx.com.